Standard escalation follows: 0.25mg weeks 1-4, 0.5mg weeks 5-8, 1.0mg weeks 9-12, with potential further increases to 1.7mg or 2.4mg based on response
Baseline laboratory evaluation should include a complete blood count with differential, comprehensive metabolic panel, hepatic function tests, and tumor markers selected according to the patients demographics, family history, and clinical context
May Release Antioxidants in the Body
Quantified Benefits: 26%50% Regrowth: The active copper peptide group achieved a "Scale 1" improvement (26-50% regrowth) compared to baseline
B12 is actually a detoxifier
Light/UV Exposure Some amino acid residues are light-sensitive (e.g., tryptophan, tyrosine) and exposure to light/UV may degrade the peptide